Discontinue Citalopram
In this patient with pre-diabetes, hypertriglyceridemia (300 mg/dL), and generalized anxiety disorder on dual SSRI/SNRI therapy, citalopram should be discontinued. She is receiving redundant serotonergic therapy with both citalopram (SSRI) and duloxetine (SNRI), which increases risk of serotonin syndrome without additional therapeutic benefit 1, 2, 3.
Clinical Reasoning
The Problem: Dual Serotonergic Therapy
This patient is taking both citalopram and duloxetine for generalized anxiety disorder—an inappropriate and potentially dangerous combination:
- Serotonin syndrome risk: Combining SSRIs with SNRIs significantly increases risk of this potentially life-threatening condition, characterized by mental status changes, neuromuscular hyperactivity, and autonomic instability 1, 2, 3
- No added benefit: Both medications work through serotonergic mechanisms; using both provides no additional anxiety control over monotherapy 1, 4
- Duloxetine is FDA-approved for generalized anxiety disorder, while citalopram is not specifically indicated for GAD 1, 3
Why Keep Duloxetine Over Citalopram
Duloxetine should be retained because:
- FDA indication: Duloxetine has specific FDA approval for generalized anxiety disorder in adults 1, 3
- Metabolic considerations: While both can affect metabolism, duloxetine may be preferable in this pre-diabetic patient
- Single agent efficacy: Duloxetine monotherapy at 60 mg daily is effective for GAD 1, 4
Why NOT the Other Medications
Chlorthalidone should NOT be discontinued despite concerns about metabolic effects:
- Her blood pressure is well-controlled (116/78 mmHg) on current therapy
- While thiazide diuretics can modestly increase fasting glucose (1.5-4.0 mg/dL) and worsen triglycerides, the 2018 ACC/AHA guidelines and ALLHAT data demonstrate that chlorthalidone remains unsurpassed in reducing cardiovascular outcomes in patients with metabolic syndrome 5, 6, 5, 7
- The small metabolic effects do not translate to increased cardiovascular risk 7
- In metabolic syndrome specifically, chlorthalidone outperformed lisinopril and amlodipine for cardiovascular outcomes 5, 6
Losartan should NOT be discontinued:
- ARBs are first-line therapy for hypertension in pre-diabetes and metabolic syndrome 8, 5, 9
- Her blood pressure control requires combination therapy
- ARBs may help prevent progression to diabetes 5
Metformin should NOT be discontinued:
- She has pre-diabetes (HbA1c 6%, fasting glucose 105 mg/dL)
- Metformin is indicated for diabetes prevention in high-risk patients 9
- It may help with weight loss (BMI 33) and improve insulin sensitivity 5, 6
Addressing the Hypertriglyceridemia
Her triglycerides of 300 mg/dL require attention but are not primarily caused by citalopram:
- The elevated triglycerides are more likely related to her pre-diabetes, obesity (BMI 33), and metabolic syndrome 5, 6, 5
- Lifestyle modification (diet, exercise, weight loss) is the foundation of treatment for both metabolic syndrome and hypertriglyceridemia 5, 6, 9
- While thiazides can modestly worsen lipids, discontinuing chlorthalidone would compromise blood pressure control without addressing the root metabolic issues
Implementation
Discontinue citalopram with appropriate taper:
- SSRIs require gradual discontinuation to avoid withdrawal syndrome (dizziness, nausea, anxiety, irritability) 1, 2
- Taper over 2-4 weeks depending on duration of use
- Continue duloxetine 60 mg daily as monotherapy for GAD 1, 3
Monitor for:
- Anxiety symptom control on duloxetine monotherapy
- Discontinuation symptoms during citalopram taper
- Blood pressure remains controlled
- Metabolic parameters (glucose, lipids) with lifestyle intervention
Common Pitfalls
- Do not discontinue the thiazide diuretic based solely on metabolic concerns—the cardiovascular benefits far outweigh modest metabolic effects in this population 5, 6, 7
- Do not continue dual serotonergic therapy—this provides no benefit and increases serious adverse event risk 1
- Do not abruptly stop citalopram—taper to avoid discontinuation syndrome 1, 2